NCT01836146已完成不适用
International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 6
- 主要终点
- Performance objective
研究概览
简要总结
The purpose of this First-in-Human Clinical investigation is to evaluate the safety and performance of the St. Jude Medical EnligHTN™ Generation 2 Renal Denervation System for the treatment of patients with drug-resistant uncontrolled hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥ 18 and ≤ 80 years of age at time of consent
- •Subject must be able and willing to provide written informed consent
- •Subject must be able and willing to comply with the required follow-up schedule
- •Subject has office Systolic Blood Pressure ≥ 160 mmHg at confirmatory visit
- •Subject has a daytime mean Systolic Ambulatory Blood Pressure > 135 mmHg during the two week screening period
- •Subject has an office Systolic Blood Pressure that remains ≥160 mmHg despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic or subject was previously on diuretic but documented to be diuretic intolerant, for a minimum of 14 days prior to the procedure and with an expectation to maintain for a minimum of 180 days post procedure.
排除标准
- •Subject has significant renovascular abnormalities such as renal artery stenosis > 30% in either renal artery
- •Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts
- •Subject has hemodynamically significant valvular heart disease as determined by the Study Investigator
- •Subject has a life expectancy less than 12 months, as determined by a Study Investigator
- •Subject is participating in another clinical study which has the potential to impact their hypertension management (pharmaceutical/device/homeopathic)
- •Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods
- •Subject has active systemic infection
- •Subject has renal arteries with diameter(s) < 4 mm in diameter or <20 mm in length
- •Subject has an estimated Glomerular Filtrate Rate (eGFR) <45 mL/min per 1.73 m2 using the Modified Diet in Renal Disease (MDRD) formula
- •Subject has Diabetes Mellitus Type I
- •Subject has multiple main renal arteries in either kidney
- •Subject has an identified secondary cause of hypertension (for example, including, but not limited to, Polycystic kidney disease, Cushing's syndrome, Aldosteronism)
- •Subject has evidence of significant abdominal aortic aneurysm (defined as maximum diameter of >4 cm)
- •Subject has had a myocardial infarction, unstable angina pectoris or cerebrovascular accident less than 180 days prior to enrollment
- •Subject is expected to have cardiovascular intervention within the next 180 days
- •Subject has a condition which would interfere with the accurate interpretation of the study objectives including but not limited to a large arm diameter that is unable to accommodate the blood pressure cuff or arrhythmia that interferes with automatic pulse sensing.
研究组 & 干预措施
Renal Artery Ablation
Experimental
干预措施: EnligHTN™ Renal Artery Ablation Catheter (Device)
结局指标
主要结局
Performance objective
时间窗: 6 months
To characterize the reduction of office Systolic Blood Pressure at 6 months post procedure as compared to baseline.
Safety Objective
时间窗: 6 months
To characterize the rate of serious procedural and device related adverse events from date of procedure through 6 months post procedure, as adjudicated by the Clinical Events Committee (CEC).
次要结局
- New renal artery stenosis or aneurysm at the site of ablation(1 month, 3 month, 6 month, 12 month, 18 month, 2 years)
- Change in Ambulatory Blood Pressure(1 month, 3 month, 6 month, 12 month, 18 month, 2 years)
- Renal Function Change(1 month, 3 month, 6 month, 12 month, 18 month, 2 years)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
IEIK13 For NeurosurgeryOozing (Hemorrhage) During Intracranial ProceduresNCT049539493-D Matrix Europe SAS80
已完成
1 期
A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsDiarrhoeaNCT05073003GlaxoSmithKline551
已完成
1 期
A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy AdultsRespiratory Synctial Virus InfectionsNCT02491463GlaxoSmithKline73
招募中
不适用
First in Human Study to Assess the Safety and the Efficacy of an Implantable Nitinol Device in the Treatment of KeratoconusKeratoconusNCT06451718Fundacio De Recerca Del Instituto De Microcirugia Ocular12
已完成
不适用
NitiNotes' EndoZip System for the Treatment of ObesityObesityNCT03472196Nitinotes Surgical Ltd.14